Showing results (21-30 of 29) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
CPT: Pharmacometrics & Systems Pharmacology|March 12, 2024
Item response theory analysis of daytime sleepiness as a symptom of obstructive sleep apneaGustaf J Wellhagen, Mats O Karlsson, Maria C Kjellsson, et al.CPT: Pharmacometrics & Systems Pharmacology|June 30, 2023
Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximabPeter N Morcos, Jonathan Moss, Rupert Austin, et al.Clinical Pharmacokinetics|November 13, 2021
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event AnalysisPaul van den Berg, Martijn Ruppert, Emir Mesic, et al.Clinical and Translational Science|April 12, 2023
Model-informed approach to support pediatric dosing for the pan-PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumorsPeter N Morcos, Jan Schlender, Rolf Burghaus, et al.CPT: Pharmacometrics & Systems Pharmacology|July 6, 2019
Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic SamplingAlexander Solms, Matthias Frede, Scott D Berkowitz, et al.Diabetes, Obesity & Metabolism|December 1, 2023
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKDThomas Eissing, Sebastiaan Camiel Goulooze, Paul van den Berg, et al.Therapeutic Advances in Cardiovascular Disease|August 1, 2019
Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndromeLiping Zhang, Xiaoyu Yan, Partha Nandy, et al.Journal of Thrombosis and Thrombolysis|April 24, 2020
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolismAlexander Solms, Stefan Willmann, Isabel Reinecke, et al.Journal of Thrombosis and Thrombolysis|April 24, 2020
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolismIsabel Reinecke, Alexander Solms, Stefan Willmann, et al.Pageof 3